Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (50257)	4/11/2002 3:32:14 PM
From: wgh613	Read Replies (1) \| Respond to of 99280

MRK, 15:10 ET MRK Merck & Co: FDA approves label changes for Vioxx (51.31 -1.83) -- Update -- FDA has approved changes to the prescribing information for Vioxx to include results from the 8,000-patient Vioxx Gastrointestinal Outcomes Research study. The FDA also has approved Vioxx 25 mg once daily for the relief of the signs and symptoms of rheumatoid arthritis in adults. FDA has approved a modification to the standard GI warning section to read "Although the risk of GI toxicity is not completely eliminated with Vioxx, the results of the VIGOR study demonstrate that in patients treated with Vioxx, the risk of GI toxicity with Vioxx 50 mg once daily is significantly less than with naproxen 500 mg twice daily."

To: Zeev Hed who wrote (50257)	4/11/2002 3:37:27 PM
From: Ditchdigger	Read Replies (2) \| Respond to of 99280

Anyone expecting a naz comp bounce off the lower BB, 1729? stockcharts.com[m,a]dallyyay[pc20!d20,2][vc60][iUb14!La12,26,9]&pref=G